Embark Delta Inc. Receives Amendment of its Licence from Health Canada Permitting Sales of Cannabis 2.0 Products Directly to Provinces & Territories
Toronto, Ontario--(Newsfile Corp. - December 4, 2020) - Embark Delta Inc., a wholly owned subsidiary of Embark Health Inc. ("Embark" or the "Company" ) is pleased to announce that it has been granted an amendment to its licence for the sale of cannabis extracts, cannabis topicals and edible cannabis products from their facility in Delta, British Columbia.
The amendment to the Health Canada licence allows the Company to further expand its existing and future product offerings to the medical and recreational consumer markets with concentrates, extracts and nanoemulsified topical and edible products. In addition, Embark can now offer white-labelling turn-key manufacturing services to its commercial accounts. Embark is currently producing Bubble Hash, Dry Sift, Traditional Pressed Hash and Rosin at their Delta facility.
"Receiving our sales licence to allow for the sale of extracts and concentrates in conjunction with EmbarkNano topicals, edibles and beverages is another key milestone in Embark's path to growth and profitability," said Dr. Luc C. Duchesne, Embark's CEO. "The Embark portfolio of products addresses the evolving needs of today's consumer."
Embark will bring products to market under the Embark Brands portfolio in order to meet the varying needs of customers; the first of which is launching in the coming weeks. "Further, the EmbarkNano team has been developing formulations to address the Health & Wellness and Beauty segments of the market," said Stephanie Fry, Embark's Chief Commercial Officer. "We look forward to these product launches in Q1 2021 and believe our products will set the standard in the market."
The team at Embark would like to thank all the people at Health Canada who have worked hard to maintain continuity despite the challenges of working under the pressures of COVID-19.
Embark Health Inc. is an emerging leader in cannabis extraction, with a focus on the formulation and production of advanced 2.0 products for the B2B and Adult-use markets. Embark continues to be at the forefront of production of solventless concentrate products including Bubble Hash, Traditional Pressed Hash, Rosin and Dry Sift. With the recent acquisition of EmbarkNano (formerly, Axiomm Technologies Ltd.) Embark is preparing to launch the next generation of Cannabis 2.0 products. Embark is preparing to launch the next generation of Cannabis 2.0 products. The acquired portfolio of products and formulations support the mass production and distribution of advanced 2.0 products including cannabis-infused beverages, topicals, edibles and water-soluble powders. For more information, please visit www.embarknano.com.
It is Embark's mandate to pursue best in class production processes resulting in premium quality commercial and consumer extraction products. Embark Health Inc. is dedicated to unleashing the full potential of the cannabis plant through scientific approaches to extraction and the production of quality products to enhance everyday life. For more information, please visit www.embarkhealthinc.com.
Investor Relations Contact:
FORWARD LOOKING STATEMENTS
This news release contains "forward-looking information" within the meaning of applicable securities laws including statements regarding the future growth and profitability prospects for Embark, the demand for Embark's products, timing for the launch and sale of its products, the success of Embark's products in the market and the ability of Embark to successfully execute its business plan. Although Embark believes in light of the estimates by management, current conditions and expected future developments and other factors, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them. Accordingly, Embark can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, changes in economic conditions or financial markets; regulatory delays; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. The statements in this press release are made as of the date of this release. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69594